Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- JCR to Develop Pompe Disease Treatment Using Blood-Brain Barrier Technology
February 24, 2017
- Kyorin Holdings to Set Up Office in Indonesia
February 23, 2017
- Takeda Assigns High-Caliber Staffers for Govt’s Community-Based Care Initiative
February 22, 2017
- Generic Picks Will Depend on Regions as Joint Purchase Gets Underway, Iwasaki Says on Teva JV
February 22, 2017
- Debiopharm Takes Nippon Kayaku to Supreme Court over Elplat
February 22, 2017
- With Positive PIII Data, AZ Aims for Olaparib’s Japan Approval in 2018
February 22, 2017
- Chugai/Roche’s Alecensa Approved in Europe
February 22, 2017
- Takeda’s Consumer Healthcare Biz Split-Off Going as Scheduled
February 21, 2017
- In Yet Another Setback, Daiichi Sankyo’s Tivantinib Fails Liver Cancer PIII
February 21, 2017
- Rexulti Approved in Canada: Otsuka
February 21, 2017
- Takeda’s Cx601 Stem Cell Therapy Shows Long-Term Effect
February 21, 2017
- Entyvio Delivers 95%-Plus Clinical Response for UC, CD at 5 Years
February 21, 2017
- Look at Value-Based Price Gap, Not Percentages, Sawai Says on Partial Revisions
February 20, 2017
- EA Pharma President Shimizu Dies at 59
February 20, 2017
- Takeda’s Ariad Acquisition Completed
February 20, 2017
- Chugai Files PD-L1 Inhibitor Atezolizumab in Japan
February 20, 2017
- Osaka Univ. Inks Another 10-Year Immunology Pact, This Time with Otsuka
February 17, 2017
- Eisai Gets Rights for 2 Orion Parkinson’s Meds in China
February 17, 2017
- Takecab Most Heavily Promoted Drug in HP Market in December: Anterio
February 16, 2017
- Takeda, PRA to Launch JV in Japan to Take Over 140 Employees
February 16, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…